<DOC>
	<DOCNO>NCT01544335</DOCNO>
	<brief_summary>The purpose study determine whether measure fluid arm use Bioimpedance Spectroscopy effective detect monitoring lymphedema measurement Perometer . The investigator also evaluate symptom may experience arm treatment breast cancer questionnaire .</brief_summary>
	<brief_title>Evaluation BIS Quantification Lymphedema</brief_title>
	<detailed_description>During study whenever arm volume measurement use Perometer , also measure fluid arm use Bioimpedance Spectroscopy . These measurement make pass harmless electrical signal low strength body determine difference amount fluid arm . The test simple painless , take 3 minute . In addition , whenever arm measurement , ask complete questionnaire . While complete questionnaire , skip question wish answer . The questionnaire take 10 minute complete . Arm measurement Perometer Bioimpedance Spectroscopy completion questionnaire occur every 4-7 month MGH regular medical visit .</detailed_description>
	<mesh_term>Lymphedema</mesh_term>
	<criteria>Histologically cytologically confirm invasive insitu carcinoma breast Participants must undergo sentinel node map axillary dissection Life expectancy great 1 year . Willingness comply require follow Perometer BIS measurement completion LEFTBC questionnaire Patients know metastatic disease locally advanced disease thoracic cervical region Any patient return routinely followup MGH DFHCC Participants know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event History primary lymphedema History prior surgery radiation head , neck , upper limb , trunk Participants evidence axillary lymph node malignancy cause lymphedema due recurrence per physician discretion Any patient bilateral lymph node map dissection Any patient current case cellulitis Patients history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>